9S5.F Fine Foods & Pharmaceuticals N.T.M. S.p.A.
- Market cap
- EUR 126M
- P/E
- -
- P/B
- 1.14x
- ROE
- -4.1%
- Dividend yield
- 2.71%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9S5.F undervalued?
Graham numberThe Graham number of Fine Foods & Pharmaceuticals N.T.M. S.p.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fine Foods & Pharmaceuticals N.T.M. S.p.A. fundamental analysis
No fundamental analysis for Fine Foods & Pharmaceuticals N.T.M. S.p.A. yet.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract manufacturing and development of oral solid forms for the pharmaceutical and nutraceutical industries in Italy. The company offers pharmaceuticals, dietary supplements, and other nutraceutical products, as well as medical devices in the form of powder or granular mixtures, film-coated swallowable tablets, chewable tablets, effervescent tablets, hard gelatin capsules, and liquids in sachets, sticks, pill conta…
Full company profileFine Foods & Pharmaceuticals N.T.M. S.p.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 195M | 207M | 252M | 244M | 252M | 250M |
| Gross Profit | 76.2M | 78.8M | 93.6M | 103M | 113M | 117M |
| Operating Income | 7.80M | 641K | 7.33M | 15.4M | 17.2M | 10.0M |
| EBITDA | - | 3.31M | 19.8M | 30.9M | 34.5M | 21.0M |
| Net Income | -1.43M | -9.50M | -3.52M | 8.16M | 10.1M | -4.76M |
| EPS | -0.06 | -0.39 | -0.14 | 0.33 | 0.42 | -0.21 |
| Balance Sheet | ||||||
| Total Assets | 303M | 300M | 242M | 243M | 280M | 317M |
| Total Liabilities | 156M | 167M | 115M | 111M | 146M | 201M |
| Shareholders' Equity | 147M | 133M | 127M | 132M | 134M | 116M |
| Cash & Short-term Investments | 17.1M | 10.2M | 19.0M | 19.2M | 38.9M | 21.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -5.83M | 3.69M | 18.5M | 45.9M | 31.8M | 15.4M |
| Capital Expenditure | 15.9M | 16.0M | 18.9M | 34.7M | 36.0M | 28.5M |
| Free Cash Flow | -21.7M | -12.3M | -330K | 11.1M | -4.24M | -13.1M |
| Ratios | ||||||
| ROE | -1.0% | -7.1% | -2.8% | 6.2% | 7.5% | -4.1% |
| ROA | -0.5% | -3.2% | -1.5% | 3.4% | 3.6% | -1.5% |
| Net Profit Margin | -0.7% | -4.6% | -1.4% | 3.3% | 4.0% | -1.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. dividends
- Dividend yield
- 2.71%
- Forward dividend
- 0.16 EUR
- Payout ratio
- 33.9%
- Ex-dividend date
- Apr 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 3.43M | 0.14 | 33.9% |
| 2024 | EUR 2.94M | 0.12 | 36.0% |
| 2023 | EUR 2.45M | 0.10 | - |
| 2022 | EUR 3.87M | 0.16 | - |
| 2021 | EUR 3.21M | 0.13 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Fine Foods & Pharmaceuticals N.T.M. S.p.A.
- Insiders 53.17%
- Institutions 9.43%
- Public & others 37.40%
- Shares outstanding 19.0M
- Free float 7.27M
Fine Foods & Pharmaceuticals N.T.M. S.p.A. company profile
- Company name
- Fine Foods & Pharmaceuticals N.T.M. S.p.A.
- Ticker
- 9S5.F
- ISIN
- IT0005215329
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Employees
- 1,123
- Fiscal year end
- December
- Address
- Via Berlino, 39, Verdellino, BG, Italy, 24040
- Phone
- 39 03 54 82 13 82
- Website
- finefoods.it
About Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract manufacturing and development of oral solid forms for the pharmaceutical and nutraceutical industries in Italy. The company offers pharmaceuticals, dietary supplements, and other nutraceutical products, as well as medical devices in the form of powder or granular mixtures, film-coated swallowable tablets, chewable tablets, effervescent tablets, hard gelatin capsules, and liquids in sachets, sticks, pill containers, jars, blisters, and strips packaging types. Its cosmetic products include toothpastes and gels, including those with microencapsulated active ingredients, single- and two-phase, alcoholic and non-alcoholic mouthwashes, and specific products for breath; skin care products, including emulsions, microemulsions, and gels; deodorants, such as solid sticks, roll-ons, and sprays; body cleansing products, including bath foams, shower gels, intimate cleansers, and liquid soaps; shampoos, conditioners, modelling waxes, and gels; and perfumery products, including perfumed body waters, eau de parfum, and after-shave. The company was founded in 1984 and is headquartered in Verdellino, Italy.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. management
2- Mr. Marco Francesco EigenmannPresident, CEO & Director
- Mr. Pietro OrianiMD & Director